-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1191 Platelets from Ehlers–Danlos Syndrome Patients Exhibit Reduced GPVI Levels and Impaired Integrin αIIbβ3 inside-out SignalingClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Bleeding and Clotting, platelet disorders, Genetic Disorders, Diseases
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Mariia Kumskova, MD, Gagan D. Flora, PhD*, Manasa K. Nayak, PhD*, Ivan Budnik, MD, PhD*, Aditi Jain, PhD*, Rakeshkumar B. Patel, PhD*, Steven R. Lentz, MD, PhD and Anil K. Chauhan, PhD

University of Iowa, Iowa City, IA

Background: Patients with Ehlers–Danlos syndrome (EDS) have a high susceptibility to bleeding. Easy bruising is included as a criterion for the classification of multiple types of EDS. Although the association between EDS and the tendency to bleed has been acknowledged for a long time, a definitive understanding of the underlying mechanisms contributing to bleeding diathesis in EDS patients is still lacking.

Objective: To characterize platelet function in a cohort of EDS patients and a murine EDS model.

Methods: A cohort of 53 patients with hypermobile (49%), classical (26%), classical-like (21%), or vascular (4%) types of EDS and a group of 53 healthy control subjects matched by age and gender were included in the study in accordance with the University of Iowa Institutional Review Board-approved protocol. The International Society of Thrombosis and Haemostasis bleeding assessment tool (ISTH-BAT) was used to assess the bleeding tendency in study participants. Because a single mutation in hypermobile type is currently unknown, we used Col5a1+/− mice as a murine model of the classical type of EDS. The function of human and mouse platelets was evaluated using standardized agonist-induced in vitro assays.

Results: The mean ISTH-BAT score was 0.1 in healthy controls and 9.2 in EDS patients (P < 0.001). An abnormal ISTH-BAT score was observed in 33 out of 53 (62%) EDS patients and 0 of 53 healthy controls (P < 0.001). Platelets from EDS patients exhibited reduced aggregation and αIIbβ3 activation (with normal αIIbβ3 surface exposure) in response to stimulation with collagen, collagen-related peptide, or thrombin receptor activator peptide-6, compared to healthy controls. Platelet secretion of dense and α-granules and surface phosphatidylserine exposure were comparable between EDS and healthy subjects. Evaluation of collagen receptors on the surface of resting platelets showed a mild deficiency of GPVI in EDS patients compared to healthy controls (P < 0.001), while the integrin α2 levels were similar in both groups (P = 0.152). Analysis of GPVI signaling revealed downregulation of Syk (Y525/526), PLCγ2 (Y1217), and talin (S425) phosphorylation in EDS patients (P < 0.05 vs. healthy controls), suggesting a defect in collagen-induced integrin αIIbβ3 inside-out signaling. Consistent with our observations in EDS patients, Col5a1+/− mice demonstrated a bleeding tendency characterized by prolonged tail-bleeding time (P < 0.05 vs. wild-type control). Platelet function testing showed that Col5a1+/− mouse platelets recapitulated the abnormalities detected in human EDS platelets.

Conclusions: Our data corroborate the observation that EDS patients exhibit a high risk of hemorrhagic complications. EDS platelets are characterized by reduced baseline GPVI expression that was associated with decreased agonist-induced platelet aggregation, αIIbβ3 activation, and impaired collagen-induced integrin αIIbβ3 inside-out signaling.

Disclosures: Lentz: Novo Nordisk: Consultancy, Research Funding; Argenx: Consultancy, Research Funding.

*signifies non-member of ASH